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The human (H) serotonin (5-hydroxytryptamine; 5HT) lA receptor (R) is implicated in 
a number of disorders including migraine headache, depression, and anxiety. H5-HT1AR 
is a member of the superfamily of G protein coupled, 7 transmembrane domain receptors 
(GPCTTDR’s) and is closely related to the beta adrenergic receptors. Because of these 
characteristics and an advanced level of study, the H5-HT1AR is a model system among 
the GPCVTDR’s and we have utilized the receptor for a series of structurally-based 
investigations.
The specific goal of the current studies is to better understand structure-activity 
relationships at the IL3 and IL2/G protein surfaces. Taking advantage of the known 
primary structure of the receptor, we have synthesized a series of peptides (P’s) from 
putative intracellular loop (IL) regions of the receptor. We have investigated the ability of 
these peptides to interfere with receptor-G protein coupling (agonist inhibition assays) 
and in some cases to directly stimulate G protein (cAMP assays; and [^^S]y-S-GTP 
incorporation). In the studies outlined here, the focus is on two new peptides (P8 and P9 
from IL3), which will be compared to previous peptides.
Additionally, Pl l ,  a partially characterized IL2 peptide, was studied in greater detail. 
PI 1 was active in uncoupling receptor from G protein, but inactive in triggering signal 
transduction. PI, P8, and P9 were active in both the uncoupling and signal transduction 
realms to various degrees. In a unique finding, P9 decreased basal levels of [^^S]y-S-GTP 
incorporation. For comparative purposes, the non-peptide dipropyltryptamine (DPT) was 
also examined as a competitive ligand-binding site agent at H5-HT1AR. These results 
supplement the fundamental hypothesis that the N-terminus of IL3 of H5HT1AR is 
critical to G protein coupling and activation, while the N-terminus of IL2 is responsible 
for coupling only.
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INTRODUCTION 
Functions of Serotonin
Serotonin (Fig. 1) or 5-hydroxytryptamine (5-HT) is an indolealkylamine 
derivative that was first recognized as a powerful vasoconstrictor occurring in blood 
serum (Erspamer, 1966). It was partially purified, crystallized, and named in 1948 
(Rapport MM, 1948), and its structure was deduced a year later. It has been functionally 
implicated in a number of disorders including migraine headache, depression and anxiety 
(Bames, 1999). 5-HT has apparent implications in Obsessive Compulsive (OCD) and 
Panic disorders (Klein, 1991). Independent work indicated that serotonin was widely 
distributed in nature and occurred in tissues other than blood. It has been shown to be in 
many representatives of the animal kingdom, in wasp stings and scorpion venom, in 
various fruits, such as pineapples, bananas, and plums, and in various nuts.
It has been estimated that an adult human contains about 5 to 10 mg of serotonin, 
90% of which is in the intestine and the rest in blood platelets and the brain (Deliganis, 
1999). One role of the compound is as a neurotransmitter, whose participation is being 
investigated in diverse functions including learning, sleep, and control of mood (Pierce, 
1989; Peroutka & S.J., 1995). The structural similarity of serotonin to several drugs 
known to cause mental aberrations, such as LSD, has prompted much speculation as to 
the role of serotonin in naturally occurring mental disorders such as schizophrenia or 
depression (van Zwieten et al., 1990)
5-HT is synthesized, from the amino acid L-tryptophan, in neurons and stored in 
vesicles. Serotonin is found in three main areas of the body: the intestinal wall; large 
constricted blood vessels; and the central nervous system. The most widely studied
effects have been those on the central nervous system. The functions of serotonin are 
numerous and appear to involve control of appetite, sleep, memory and learning, 
temperature regulation, mood, behavior (including sexual and hallucinogenic behavior), 
cardiovascular function, muscle contraction, endocrine regulation, and depression (Shih 
JC, 1995). In some cases, 5-HT’s role is modulatory; however, there are cases such as 
sleep and in certain types of hallucination, where 5-HT function appears to be the 
primary determinant.
N K
HO
Figure 1 
5-HYDROXYTRYPTAMINE
5-HT Receptors
There were initially 2 receptors which were found to mediate the actions of 
serotonin (Gaddum & Picarelli, 1997). With progress of years of research and the 
employment of radiolabled ligands a third class of the 5-HT receptors was identified 
(Peroutka et al., 1979). The last decade has seen the identification of numerous new 
subtypes of the 5-HT receptor. This was possible mainly due to the advancement of 
molecular biological techniques (Wishart, 1999). Currently there are seven types of the 
receptor which is further classified into various subtypes (Hoyer D, 1994). Most of these 
subtypes were classified based on their pharmacological activity (Hoyer D, 1994). Some
subtypes were initially identified by sequencing cDNA-deduced primary amino acid 
sequences (Peroutka & S.J., 1995) and in other cases, similarities in signal transduction 
assisted in classification.
All the 5-HT receptors except the 5-HT3 receptor belong to the superfamily of 7 
transmembrane G-protein coupled receptors (Maricq et al., 1991; Hoyer D, 1994). The 5- 
HT3 receptor is closely linked to G ABA, AMPA/kainate, cholinergic (nicotinic) and 
glycine receptors, which fall under the category of ion-channel receptors. The 5-HT3 
receptor, like all ligand-gated receptors, has a large glycosylated extracellular N- 
terminus, with 4 subsequent transmembrane segments (Maricq et al., 1991)
Extr»c#4lular
r 0 ■ *• o ---- o ' "  « '
U ■
. . "O' 0  . ;0 .o
, 0OO. 00
1 fs.0 p 0  : : 0  0 : - ‘ ' o  0.O i 0 0 0■. . 0
* ■ b
. o
0 o %
Figure 2
2-DIMENSIONAL REPRESENTATION OF A TYPICAL GPCR, SHOWING THE 
HYDROPHOBIC DOMAINS INSERTED INTO THE PLASMA MEMBRANE
The 5-HT receptors (excepting 5-HT3) belonging to the 7 transmembrane family 
are coupled to heterotrimeric guanine nucleotide binding G-proteins. (Strader, 1994). The
superfamily of G-protein coupled receptors (GPCRs) constitutes the largest class of cell 
surface receptors, and thus represents the primary mechanism by which cells sense and 
respond to their external environment (Fig. 2)(Marchese, 1999). GPCRs transduce their 
signals across the plasma membrane via an interaction with heterotrimeric G-proteins, 
which leads to an activation of intracellular effectors such as adenylyl cyclase (AC) or 
phospholipase C (PLC) and subsequent generation of second messengers such as cAMP 
(cyclic adenosine-monophosphate) or calcium (Dratz, 1993). These effects are amplified 
and transmitted down through a cascade of intracellular events leading eventually to the 
physiological response of the cell to the stimulus (Marinissen & Gutkind, 2001).
The enormous diversity of receptors, G-proteins and effectors, together with the 
widespread distribution of receptors across many tissues,(Nebigil et al., 1995) reflects the 
important role that this family of proteins plays in regulating physiological and 
pathophysiological processes (Martin, 1999). Table I lists the various G-proteins which 
couple with multiple 5-HT receptor subtypes and their functions. These GPCRs possess a 
multiple glycosolated extracellular amino terminus (N-terminus) and intracellular 
carboxy tail. They are comprised of 7 transmembrane (TM) domains (Fig. 3) which form 
a helices arranged in distorted cylinder like fashion, the extracellular side of this core 
forming the ligand-binding domain (Baldwin, 1994)
G Protein Coupled Receptors
3 intracellular loops (IL) are located between the transmembrane helices (Bourne,
1997). These loops are the putative sites of interaction with the heterotrimeric G-protein. 
The structure of the GPCR’s have been an challenging to elucidate, because they are
membrane bound and difficult to crystallize. The bacteriorhodopsin model was an 
excellent first representation of the 7TM/GPCR. Though the bacteriorhodopsin model is 
not G-protein coupled, it has been a very useful initial evaluation tool of all GPCRs in 
general. Rhodopsin,(Palczewski et al., 2000) which is G-protein coupled is now the 
accepted prototype for this class of receptors (Acharya et al., 1997; Bamidge, 1997; 
Unger, 1997).
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BALDWIN ARRANGEMENT OF 7 A-HELICES IN GPCR
G-proteins are composed of three subunits (alpha, beta and the smaller gamma 
subunits)(Bikker, 1998). Beta and gamma are, in turn, tightly associated as a dimer. The
alpha subunit shares homology with the GTPase family, possesses intrinsic GTPase 
activity and contains sites for myristoylation and palmitoylation (Casey, 1995). All 
gamma subunits contain sites for isoprenylation . These acétylations target G-proteins to 
the membrane compartment, the principal site for G-protein signaling. Four G-protein 
subfamilies have been identified and classified according to the known 23 alpha subunits 
(Gq/11, Gi/0 Gs and G 12/13) (Mulheron, 1994). There are a similar variety of beta and 
gamma subunits, which are classified according to association with alpha subunits. These 
G-protein subfamilies can be either stimulatory (Gq/1 l,Gs) or inhibitory (Gi/0) (Burstein 
et al., 1996).
Ligand binding results in a conformational change in the receptor cytoplasmic 
domain (Sheikh SP, 1996) (Farrens, 1996) that promotes association with an inactive 
GDP-bound heterotrimeric G-protein (Fig 4). This interaction enhances dissociation of 
GDP from the receptor/G-protein complex, facilitating GTP binding, alpha subunit 
activation, (Onrust et al., 1997) and dissociation from the receptor. Dissociation of G- 
protein from the receptor results in alpha subunit dissociation from the trimeric complex, 
facilitating its interaction with effector molecules such as AC. Intrinsic alpha subunit 
GTPase activity catalyses GTP hydrolysis causing inactivation, a process often enhanced 
or activated by effector binding. The GDP-bound alpha subunit re-associates with beta 
and gamma subunits to form an inactive G-protein heterotrimer, which is once again 
capable of interacting with the receptor. (Bowler et al., 1998). It is critical to note for the 
work discussed in this thesis, that the G-protein bound form of the receptor has high 
agonist affinity, while the uncoupled receptor has a lower affinity state.
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Figure 4
SCHEMATIC REPRESENTATION OF A GPCR, THE GTP CYCLE AND
LINKAGE TO AN EFFECTOR, ADENYLYL CYCLASE.
5-HTlA Receptor
The 5-HT 1A receptor is one of the most studied receptor types among the 5-HT 
receptors. Structurally, as mentioned in the previous paragraph, the 5-HT 1A receptor is a 
member of the superfamily of G-protein coupled 7 transmembrane domain receptors and 
is closely related to P adrenergic receptors (Kobilka, 1987; Fargin, 1988; Raymond, 
1999) Human (H) 5-HTlAR is intronless and codes for a core sequence of 422 amino 
acids, yielding a molar mass of about 46,000. The actual molecular weight, however, is 
much higher as the extra-cellular N-terminus is heavily glycosylated.
The receptor is negatively coupled to adenylyl cyclase, and principally causes 
hyperpolarization (Sanders, 1998). In the CHO cells used in this study(Raymond et al., 
1993), Gin's 2 and 3 are the primary coupling subunits (Arthur et al., 1993). There is also 
evidence that some 5-HT 1A receptors are positively coupled to adenylate cyclase; this 
may be accounted for either by the existence of different types of 5-HT 1A receptors or 
the coupling of 5-HT 1A receptors to different G-proteins (Zifa & Pillion, 1992). 
Interestingly, 5-HT 1A receptors in the raphe nuclei, act as somatodendritic autoreceptors 
which inhibit neuronal cell firing and 5-HT release onto postsynaptic sites.
Several agonists show selectivity for the 5-HT 1A receptor, particularly 8- 
hydroxy-di-n-propylamino tetralin (8-OH-DPAT), which acts as a full agonist in most 
systems, while the non-benzodiazepine anxiolytics, buspirone, ipsapirone and gepirone, 
and other ligands such as MDL 72832 are partial agonists. The synthesis of selective and 
silent antagonists at this receptor has proved more difficult. Several apparent antagonists 
have been characterised, such as NAN 190, BMY 7378, MDL 73005EF, WAY 100,1^ ,̂
8
UH 301, spiroxatrine and SDZ 216525. However, all have demonstrated partial agonist 
properties in studies of somatodendritic autoreceptor function, perhaps due to the much 
larger receptor reserve associated with these as opposed to postsynaptic receptors. To 
date, the only selective high affinity silent antagonist at this receptor is WAY 100,6^  ̂
(Fletcher et al., 1993).
5-HTlA Receptor-G-Protein Interface:
The major aim of this thesis is to better understand the 5-HTl AR-G-Protein Interface. To 
better understand the dynamics of this system, we have designed putative peptides 
(Taylor & Neubig, 1994; Palm D, 1995), which mimic various portions of the 
Intracellular-Loops of the 5-HTl AR. To particular interest to our thesis was Intracellular 
loop 3 (IL3) and also to a small extent Intracellular loop 2 (IL2). There is very strong 
evidence that G-Proteins interact at these loops (Merkouris et al., 1996; Thompson,
1998). Our interest was to zoom into these sites of interaction and identify putative 
regions of both IL2,(Lembo et al., 1997) where the loops are responsible for coupling or 
activation of G-Protein or both. Fig 5 describes in detail, the various regions of interest of 
the Human 5-HTl A Receptor-G-Protein Interface.
The putative peptides when administered into the cell, will compete with Intracellular 
loops to couple to G-Protein. If the peptides are representative of regions on Loop 2 
where G-Protein couples, the peptide will uncouple G-Protein from Intracellular loop(s). 
This uncoupling of G-Protein from the Intracellular loops will result in a decrease in the 
affinity of the receptor for its ligand (8-OH-DPAT in our case). This in other words is an
indirect Agonist Inhibition effect. Thus by estimating the ‘Agonist Inhibition’ effect of 
these peptides we will be able to estimate the uncoupling properties of these peptides.
Activation of G-Protein will result in the G-Protein to couple to its effector (Adenylyl 
cyclase in our case). This will result in cascade of signaling events resulting in producing 
of a signaling response. In our system, since the 5-HTlAR is negatively coupled to 
Adenylyl cyclase, the signal would be a lowering of intracellular cAMP. Thus if the 
putative peptides represent a region of the Intracellular loop(s) responsible for activation 
of G-protein, the peptide should activate G-Protein by itself. Activation of G-Protein is 
also estimated by Incorporation of y-S-GTP. Details of this approach are explained in 
Methods.
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TABLE I: Major signal transduction oathwavs for serotonin receptors
Receptor Subtvoe G-orotein Effector pathway
5-HT1a Gi Inhibition of adenylate cyclase
Gi Opening of K+ channel
Go Closing of Ca2+ channel
5-HT1b Gi Inhibition of adenylate cyclase
S-HTloa Gi, other ? Inhibition of adenylate cyclase
5-HTlop Gi (probably same 
as 5-HTlb)
Inhibition of adenylate cyclase
5-HT1e Gi Inhibition of adenylate cyclase
5-HT1f Gi Inhibition of adenylate cyclase
5-HT2a Gq Phosphoinositide hydrolysis, i  conductance
5-HT2b Gq Phosphoinositide hydrolysis, T intracellular Câ "̂
5-HT2c Gq Phosphoinositide hydrolysis, -I conductance
5-HT3 No G-protein Ligand-gated ion channel
5-HT4 Gs Activation of adenylate cyclase
5-HT5a ? Both AC and IP3 systems implicated at this point
5-HT5b ? Both AC and IP3 systems implicated at this point
5-HT6 Gs Activation of AC
5-HT7 Gs Activation of AC
Adapted from : Sanders-Bush, E; Canton, H. 1995, Serotonin receptors. Signal 
transduction pathways in: Psychopharmacology: the Fourth Generation o f Progress, Ed. 
by Bloom F  and Kupfer D. Raven Press, New York, pp: 431-441.
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SPECIFIC AIMS
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Figure 5
SCHEMATIC REPRESENTATION OF THE LOCATION OF VARIOUS PEPTIDES 
OF INTEREST AND THEIR REPRESENTATION OF THEIR RESPECTIVE 
REGIONS IN INTRACELLLULAR LOOPS 2 AND 3 OF THE 5-HTlAR
Peptides PI 1 represents the N-terminal end of Intracellular loop2. Peptides P1,P8 and P9 represent the 
native region N-terminal end of Intracellular loop 3. P8 and P9 are substitutes and truncates of Peptide 
PI
1 2
SPECIFIC AIMS
A. To determine the uncoupling (agonist inhibition) and signal transduction 
(cAMP) capabilities of peptides P8 and P9.
B. To examine the concentration-dependency of agonist inhibition for P8 and P9 as 
well as parent peptides PI and P ll.
C. To develop GTP incorporation assays for studying peptide stimulation of G 
protein (peptides PI, P8, P9, and PI 1 will be utilized).
P e p t id e Se q u e n c e
P I
P8
P9
P l l
I F R A A R F R I R K T V K K
Y G R I F R A A R F R I R K T V K K
R F R I R K T V K K
l A L D R Y W A I T D
TABLE II
PRIMARY SEQUENCES OF VARIOUS PEPTIDES INVESTIGATED
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MATERIALS AND METHODS 
Materials
Culture Media and Reagents:
Hams F-12 Medium (FI2); Dulbecos Modified Eagle Medium (DMEM); Earles 
Balanced Salt Solution (EBSS); Trypsin -  GIBCO/Life Technologies, Grand Island, New 
York. Calf Serum (CS); Fetal Bovine Serum (FBS) -  Summit Biotechnology , Fort 
Collins, CO. Geneticin (G ' ÎS Sulphate) -  Calbiochem, La Jolla, California
Reagents:
HEPES buffer -  U.S. Biochemical, Cleveland, Ohio. EDTA; Tris Buffer; CaC12; 
Diethyl ether—J.T. Baker, Phillipsburg, New Jersey. Mianserin; Pargyline; 
Isobutylmethylxanthine (IBMX); Sodium Deoxycholate; Aprotonin; Leuepeptin 
Benzamidine; Forskolin -  Sigma Chem Co, St. Louis, MO. [3H]Ketanserin; [3H]8-OH- 
DPAT; [^^S]y-S-GTP-NEN, Boston MA. DMSO- Mallinckrodt, St. Louis, Missouri. 
EIA Direct cAMP Kit-Assay Designs, Ann Arbor, ML Serotonin- ICN Pharmaceuticals, 
Irvine CA.
Other:
All other reagents were standard scientific grade, typically from general scientific 
supplies such as VWR and Fisher. Glassware, small apparatus, and any additional items 
were scientific grade from standard suppliers.
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Methods
Cell Culture
Chinese Hamster Ovary (CHO) cells (transfected with the H5HT1A receptor 
gene) were obtained from Dr. John Raymond, Medical University of South Carolina. 
They were sub-cultured as a monolayer in 80 cm2 or 175 cm2 flasks. The medium for 
cell culture for this cell line was Ham’s F-12 medium. Medium was fortified with 10% 
Fetal Bovine Serum and 200 py/ml Geneticin for selection of the transfected phenotype. 
Cultures were incubated at 37°C under a humidified atmosphere of 5% C02, 95% air. 
The cells were plated to reach confluency in approximately 7 days. At confluency, the 
cells were harvested using trypsin (0.25%) and used for assay or sub-cultured for later 
experiments.
Receptor Preparation
The first step of the assay is to prepare receptors from transfected CHO cells. 
Harvested cells were maintained at 4°C until utilized for the assay. The cells were 
sedimented in a super speed centrifuge @ 2000 RPM following dilution with ice-cold, 
serum-fortified medium at 4®C for 10 minutes. The pellet resulting from this spin was 
resuspended in Earle’s Balanced Salt Solution (EBSS) and again centrifuged for 10 
minutes at the same speed. Based upon the receptor preparation desired, the cells 
obtained from the above rinsing procedure were treated as follows:
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A: Whole Cells: The cells were gently suspended in 30 mis of ice cold binding 
buffer (50 mM Tris, pH 7.4; 4 mM CaC12; 10 pM pargyline). The cells were used 
directly in the assay
B: Membranes: Homogenization of the cells results in a crude membrane 
preparation of the receptor. This was done by resuspending the rinsed cell pellet in ice- 
cold binding buffer, homogenization on teflon-glass, and centrifugation at 5000 RPM for 
a period of 45 minutes at 4°C. This results in lysing of the cells. The final crude 
membrane fraction was re-suspended in 30 mis binding buffer and subjected to 
homogenization, first, on teflon-glass followed by brief exposure to a Brinkmann 
Polytron at setting 5 for a period of 10 seconds.
C: Solubilized Receptor: Cells were placed in 1 ml of solubilizing buffer (20 
mM Tris, pH 8.0; 0.6% sodium deoxycholate; 1 mM EDTA; ImM dithiothreitol; 100 
mM NaCl; 1 mM benzamidine; 10 pg/ml leupeptin; 100 mg/ml soybean trypsin inhibitor; 
and 10 pg/ml aprotinin) on ice for 1 hour (Mulheron et al., 1994 ). The mixture was then 
centrifuged for 300,000g-min. The supernatant, which carries the solubilized receptor, 
was removed, diluted with 30 mis of ice-cold binding buffer, and mixed gently prior to 
assay.
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Li^and-Receptor Binding Assay (Agonist Inhibition)
As described in the Introduction section, the basis for Agonist Inhibition assays is 
that the peptides when uncoupling the G-Protein from the receptor will result in the 
lowering of the affinity state of the receptor f  In our study we have used tritiated 8- 
hydroxy-2-(di-n-propylamino)tetralin [3H]8-OH-DPAT as the agonist and performed 
Agonist Inhibition assays to determine the uncoupling effect of the peptide. The 
displacement of [3HJ8-OH-DPAT will indicate the affinity state of the receptor. An 
important point to note here is that the peptides were expected to uncouple G-Protein and 
change affinity rather than compete with [3H]8-OH-DPAT at the ligand-binding site.
The displacement of [3H]8-OH-DPAT from the receptors was determined using 
established protocols (Pierce, 1989; Hayataka, 1998; Ortiz, 2000). The assays were 
carried out by combining 700 pi receptor preparation, 100 pi binding buffer (total 
binding) or 100 pi binding buffer containing 10 pM serotonin (to determine non-specific 
binding), 100 pi of peptide (various concentrations), and 100 pi of [3H]8-OH-DPAT 
(varying concentrations), yielding a total volume of 1 ml. The mixture was made in 
triplicates and incubated at 30°C for a period of 30 mins. The assay was then stopped 
using 4 ml of ice-cold Tris buffer (50 mM, pH 7.4) followed by immediate vacuum 
filtration over Whatman GF/B filters (GF/F in the case of solubilized receptor). This was 
followed by 2 washes with 5 ml of buffer. The filters were then counted in 5 mis of 
Ecoscint liquid scintillation fluid in a Beckman LS 6500 scintillation counting system. To 
achieve a nominal value of 50 pg/filter, receptor preparation proteins were determined by 
the Bradford colorimetric method (1976).
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cAMP Assay
Confluent, intact CHO cells were used to determine cAMP formation. Medium 
from cells grown in 24-well plates was removed. After two rinses with serum-free 
medium, cells were treated with 0.5 ml serum-free medium containing 100 pM 
isobutylmethylxanthine (IBMX), and one or more of the following agents (final cones.): 
forskolin (30 pM); 5-HT (0,1-10 pM); peptides (various concentrations). Incubation with 
agitation proceeded for 20 min. at 37°C. The reaction was stopped by aspiration of the 
medium, and the cells were incubated with 0.5 mis of 100 mM HCl for 10 min. at room 
temperature. Well contents were removed and centrifuged at 4000 rpm for 15 min. at 
room temperature. Aliquots of supernatant were used to determine cAMP in a direct 
enzyme-linked immunoassay with a kit from Assay Designs. The microplate was read at 
405 nm with a 96-well reader.
y-S-GTP Binding Assays
y-S-GTF binding assays were designed to verify if the peptides activated G-Protein. 
Though this was accomplished by cAMP assays to a far extent, these assays are rather a 
more direct method of measurement of G-Protein estimation than cAMP assays. 
Normally the G-Protein incorporates some basal GTP as part of their GTP-GDP cycle. 
Receptor stimulation will result in an increased incorporation of GTP. Thus by measuring 
the amount of G-Protein will indicate the degree of activation of the receptor. In actual 
conditions GTP possesses intrinsic GTPase activity hence for our experiments we used a 
stable analog of GTP - y-S-GTP. The incorporation of y-S-GTP is an outcome of the 
activation of G-Protein by the peptides.
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The steps involved in the cell culture/harvesting were identical to the agonist 
inhibition assay until we reached the point of centrifugation with binding buffer. At this 
point the cells were centrifuged using HEPES buffer (20 mM HEPES, pH 7.4; 5 mM 
MgC12; 1 mM EDTA; 1 mM dithiothreitol; 100 mM NaCl; 10 pM GDP; 10 pM pargyline; 
0.2 mM ascorbate) at the same speed and time as in the agonist inhibition assay. After this 
step, the crude membranes were re-suspended in 15 mis of HEPES buffer, and 
homogenized with a Teflon-glass homogenizer. In the assay (Wieland, 1994), ^̂ 0 pi of the 
crude membranes were combined with 50 pi of peptide solution (various concentrations) 
and/or 5-HT (various eoncentrations) and 100 pi of 0.1 nM [^̂ S] y-S-GTP and incubated 
for 30 min. at 30 °C. The mixture was filtered on GF/C filters, and washed twiee in buffer 
followed by drying and liquid scintillation counting. Negative control was the above minus 
the peptide. Non-specific binding was determined in the presence of cold y-S-GTP (10 
pM). Positive control was H5-HT1AR membranes in the same incubation mixture plus 0.1- 
10 pM 5-HT.
Peptide Synthesis and Preparation
Peptides were synthesized at the University of Montana’s Murdock Molecular 
Biology facility utilizing modifications of classical solid phase techniques (Marglin & 
Merrifield, 1970; Ortiz, 1999) on an ABI 431A automated peptide synthesizer. Following 
synthesis, peptides were solvent extracted and subjected to chromatography in 
acetonitrile/2mml/l HCL gradients with a Waters 625 HPLC System. Peptides were 
lyophilized and stored desiccated at -20°C. For use, peptides were initially dissolved in de­
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ionized water or 5% DMSO. Subsequent dilutions of peptides were in binding buffer. 
Control experiments revealed no effect of DMSO in the assay systems at the highest final 
concentration of DMSO (0.5%).
Data Analysis
Results of binding experiments are expressed as percentage of controls. IC50s 
were determined from non-linear regression analysis of dose response curves. Inversion 
plots were analyzed by best-fit regression analysis, with results expressed as ratios using 
maximal binding in absence of inhibitor as reference value. For cAMP quantification, 
standard curves were prepared and subjected to linear regression analysis. Results are 
expressed as percent of forskolin-stimulated controls. In the case of y-S-GTP 
incorporation, results are expressed as percent of basal incorporation (i.e. the control 
value when 5-HT or other experimental ligands are absent). In all cases both computer 
assisted and manual data analysis occurred. Statistically, results are expressed as mean 
plus or minus standard error of the mean. When significance was determined, a two- 
tailed Student’s t-test was utilized.
2 0
RESULTS AND DISCUSSION 
Peptide P8
Hypothesis
P8 represents a segment of H5-HTlAR’s native IL3 responsible for both receptor- 
G protein coupling and G protein activation. Its activity will be superior to PI.
Sequence
YGRIFRAARFRIRKTVKK
Introduction
Peptide P8 is structurally similar to parent peptide PI from the TM5/IL3 interface, 
except that P8 has an additional three amino acids at the N-terminal end. The interface 
between transmembrane segments and intracellular loops is hypothetical. Based upon 
hydropathy analysis, putative designations between TM segments and IL’s have been 
assigned. Additionally, there is thought that the boundary is indistinct, perhaps changing 
slightly depending on environmental circumstances the receptor is exposed to. Therefore, 
we thought it wise to probe a short distance into the putative membrane region to explore 
whether this change increased or possibly decreased the activity of PI. P8 is the longest 
peptide that we have used. The overall expectation of this peptide was that it would very 
much behave like P 1 and if it did or did not, we could further hypothesize on the role of 
the N-terminal end of the peptide sequence in coupling and/or activation.
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Agonist Inhibition/Concentration-Dependencv
Similar to results previously determined with PI (Hayataka et al. 1998), PS 
demonstrated concentration-dependent agonist inhibition in membrane preparations of 
H5-HT1AR (Fig. 5). As with other peptides, agonist inhibition was examined in all three 
receptor preparations (Table III).
Peptide ICso (pmoI/L)*
% Inhibition 
Of Forskolin 
Stimulated 
cAMP*
% Change in 
y-S-GTP
Incorporation
@
Whole Cell Membrane Solubilized
1 3 ± 2 24 ± 7
P8 .8 ± 4 5 ± 2 2 7 #
TABLE III: SUMMARY OF RESULTS FOR PEPTIDE PS FROM THE TM5/IL3 
REGION OF THE HUMAN 5-HT 1A RECEPTOR
‘whole cell, membrane, and solubilized indicate the preparation of receptor in which the IC50 was 
determined; n ’s = 3-5 unique preparations in each case. ^Expressed as percent inhibition relative to controls 
treated with 30 pmol/L forskolin (FSK). ^Expressed as percent of background incorporation. ^Maximum 
Inhibition @ 10'  ̂M
Overall, the range of these results (micromolar ICSO’s for whole cell and 
membrane receptor preparations) is similar to PI (Hayataka, 1998). However, there is an 
un-anticipated aspect to these results. Whole cell preparations were the most sensitive 
followed by membrane preparations with solubilized receptors being the least sensitive. 
This is arguably, an unusual expectation for P8, as the order of sensitivity is opposite to 
that seen for the parent, PI. While the result with solubilized receptors is incomplete due
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to the difficulty of working with this poorly soluble peptide in the labile solubilized 
preparations, P8 appears to be less active against solubilized receptors compared to either 
of the other receptor preparations. It is distinctively possible that the anomalous result for 
P8 in solubilized preparations is an artifact of the difficulty in working with these labile 
receptors. Nevertheless, the order of sensitivity for P8 inhibition in membrane and whole 
cell receptor preparations is still reversed compared to PI.
The inversion plots adapting the Lineweaver-Burke formulation of enzyme 
kinetics (Fig. 6) provided a similar result to that seen for P9 (later this thesis). However, 
it has a small similarity to the parallel lines of PI 1 (later this thesis). From these results, 
we hypothesize that P8 is a non-competitive inhibitor at the H5-HT1AR. From this 
conclusion we further postulate that P8 binds to an allosteric site in the receptor complex 
and not at the ligand binding-site. However, the unusual order of sensitivity between 
receptor preparations remains unexplained, and the possibility that P8 interactions with 
the H5-HT1AR/G protein complex are more varied than indicated by non-competitive 
mechanisms is distinctly possible.
cAMP Determination
Figure 7 indicates the results of cAMP assays with PS and 5-HT. PS did not 
significantly inhibit forskolin-stimulated cAMP. Although the results indicated a trend 
towards inhibition of cAMP formation, variability is too great to accept the hypothesis 
that cAMP production is decreased. Thus, PS may be not be able to activate G-protein by 
itself, or if it can, its ability is limited. Although the results with PI were significant
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(Hayataka, 1998), the trend is very similar to P8 in that PI was able to decrease cAMP 
formation very modestly.
y-S-GTP Incorporation
P8 and 5-HT both stimulated incorporation of [^^S]y-S-GTP into membrane 
preparations of H5-HT1AR (Fig. 8). P8, however, was not as effective as 5-HT, but it did 
incorporate y-S-GTP on its own. This result reinforced the trend observed with cAMP 
studies. That is, while the activation of G, and subsequent decrease in cAMP 
concentration was not statistically significant, it is possible that a significant result could 
have been obtained with larger n. Thus, it is possible that P8 is weakly active in 
stimulating Gj, much like PI.
Hypothesis Modification
P8 is not more active in triggering signal transduction than PI. Although the 
results between cAMP determinations and y-S-GTP incorporation experiments are mixed, 
the trend seems to be that P8 was modestly active in triggering signal transduction. In the 
area of agonist inhibition, P8 and PI seemed to be quite similar, although P8’s order of 
results between receptor preparations suggests something unusual is happening. The 
modified hypothesis is that P8 represents a segment of H5-HT1AR responsible for 
coupling to and activating G protein, and that its activity is similar to PI. Currently, we 
conclude that adding three amino acids to the N-terminus of PI made little difference in 
P i ’s biology. As is the case with all of these peptides, final issues regarding the
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determinants and site(s) of binding will not be completely resolved until additional 
experiments with cross-linking and high resolution spectroscopy are performed.
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Figure 6
DISPLACEMENT OF (’H)-8-0H DPAT BY PEPTIDE P8 IN MEMBRANE 
PREPARATIONS OF THE HUMAN 5-HT lA  RECEPTOR.
Results shown are means +/- SEM, with n’s of 2-5. Experimental conditions are outlined in Methods. 
Summary results for P8 are listed in Table III.
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Figure 7
C O N C EN TR A TIO N -D EPEN D EN C Y  OF SPECIFIC I^H]8-OH-DPAT BIND ING  IN THE  
PR ESENCE O F P8 IN M EM BRANE PR EPAR ATIO N S O F H5H T1AR.
X-axis: Inverse concentration of the ligand, [^H]8-OH-DPAT in 1/nmol/L. Thus, 1 corresponds to 1 nmol/L 
whereas 5 corresponds to 0.2 nmol/L. Y-axis: LR is the concentration of the Ugand-receptor complex; LR 
max determined by Scatchard analysis. The axis was originally plotted as the dimensionless ratio: 1/LR/LR 
max. The lower line (♦ - ♦ )  is control [^H]8-OH-DPAT binding in the absence of P8. The middle line (□ [) 
is the [^H]8-OH-DPAT binding in the presence of 10’̂  P8. The upper line (A-A) is [^H]8-0H-DPAT 
binding in the presence o f 10  ̂ P8. All experiments were completely run at least twiee in triplicate. 
Correlation coefficients for the lines are all above 0.99. Experimental conditions are outlined in Methods.
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Figure 8
INHIBITION OF FORSKOLIN-STIMULATED cAMP ACCUMULATION OF 
5HT AND PEPTIDE P8 IN WHOLE CELL PREPARATIONS OF THE HUMAN
5HT1A RECEPTOR.
Results are mean +/- SEM from 3 experiments run in duplicate or triplicate. Values are expressed as 
percent of forskolin (FSK)-stimulated cAMP. All conditions contained forskolin (30 pmol/L). 5-HT 
concentration was 1 pmol/L. P8 concentration was 10 pmol/L. Other experimental conditions are outlined 
in Methods. Summary results for PS are shown in Table III.
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Figure 9
[^®S]y-S-GTP INCORPORATION INTO H5HT1AR MEMBRANES
BY 5HT AND P8.
Results are mean +/- SEM of 2 experiments, all run in triplicate. Values are expressed as percent of [^^S]y- 
S-GTP incorporated in controls (basal) lacking 5-HT or P8. [^^S]y-S-GTP concentration in all conditions 
was 0.1 nmol/L, 5HT concentration was 0.1 pmol/L. P8 concentration was 10 pmol/L. *P8 significantly 
different from control (p<0.05). Other experimental conditions are outlined in methods. Summary results 
for P8 are found in Table III,
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Peptide P9
Hypothesis
P9 represents a truncated region of H5-HTlAR’s TM5/IL3 interface that is modestly 
active in coupling but inactive in activation of cognate G protein.
Sequence
RFRIRKTVKK
Introduction
Peptide P9, along with P8, is one of the primary molecules to be explored in 
this thesis. P9 is a naturally occurring segment of the TM5/IL3 region. It is a truncated 
version of the parent peptide from this region, PI. Unlike PI, however, P9 has the first 5 
amino acids from the N-terminus of IL3 deleted. The remaining 10 amino acids represent 
the “hot” spot at positions 6-9, plus the remaining 6 amino acids in the C-terminal portion 
o fP l.
The basic premise behind P9’s synthesis was that the role of the first 5 amino acids 
in PI could be tested by measuring activity in their absence. Before testing P9, we 
postulated that it would be active in uncoupling receptor from G protein, but likely less 
capable than PI. We further hypothesized that it was unlikely to be active in triggering 
signal transduction, as all truncated peptides examined at that point (Ortiz et al., 2000) had 
lacked activity. As the results given below show, this hypothesis needs some modification.
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Agonist Inhibition/Concentration-Dependencv
Figure 9 demonstrated concentration-dependent agonist inhibition by P9 in 
membrane preparations of H5-HT1AR. As with other peptides studied earlier, agonist 
inhibition by P9 was also examined in whole cell and solubilized receptor preparations. 
Table IV indicates the ICSO’s of P9 with various preparations of H5-HT1AR. The IC50 
of 25 pM for P9 in membrane preparations compares to P i ’s IC50 of about 3 pM 
(Hayataka et al., 1998). Thus, P9 is over 8 times less active than PI in receptor/G protein 
uncoupling.
Peptide ICso (pmoI/L )*
% Inhibition 
of Forskolin 
Stimulated 
cAMP*
% Change in 
y-S-GTP 
Incorporation®
Whole Cell Membrane Solubilized
-8 ± 5 - 1 7 ±  I
P9 60 ± 4 25 ± 2 30 ± 3
TABLE IV: SUMMARY OF RESULTS FOR PEPTIDE P9 FROM THE TM5/IL3 
REGION OF THE HUMAN 5-HTl A RECEPTOR
'w hole cell, membrane, and solubilized indicate the preparation of receptor in which the IC50 was 
determined; n ’s = 3-5 unique preparations in each case. ^Expressed as percent inhibition relative to controls 
treated with 30 pmol/L forskolin (FSK). ^Expressed as percent of background incorporation.
Whole cells were the least sensitive of the receptor preparations with respective to 
agonist inhibition of peptide P9. This may suggest that there is some difficulty in the 
peptide P9 traversing membranes. The differences among the three forms of receptor
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preparation were relatively small when compared against the other peptides studied 
earlier (Hayataka et aL, 1998; Ortiz et al., 2000). This could be due to the fact that P9 is a 
comparatively shorter peptide. Because of the relative closeness of IC50 values for P9 in 
different receptor preparations, and the large differences seen with PI, P9 was about 60 
times less active than PI at solubilized receptors.
Figure 10 gives us an idea about the type of inhibition produced by peptide P9 at 
membrane preparations of H5HT1AR. By comparing the reciprocal plots of [^H]8-OH- 
DPAT concentration to that of 8-OH-DPAT -  5-HTlAR complex concentration in 
the adaptation of the Lineweaver-Burke plots of enzyme kinetics, it can be inferred that 
P9 produced non-competitive inhibition. However, this binding is complex, and there is a 
chance that further experiments may reveal mixed inhibition characteristics. Our best 
hypothesis at this time is that P9 is binding to some allosteric site in the receptor complex 
and hence shows non-competitive interactions.
Scatchard analysis has been a standard method for analyzing equilibrium binding 
parameters of drugs with receptors. The Scatchard plot is a graph of (on the y axis) the 
amount of radioligand bound divided by the amount of radioligand free in the solution, 
versus (on the x axis) the amount of radioligand bound. The Bmax value is equal to the 
intercept on the x-axis when y = 0, and the absolute value of the slope is equal to the 
1/K d value. Linearity of the line indicates that a drug binds to a single site. We performed 
Scatchard analysis on every binding experiment done with every peptide; thus there 
would be scores of Scatchard plots if we were to present every one of them. Scatchard 
analysis was performed mainly to calculate maximal binding (Bmax) information, which 
was further used in the inversion calculations. It is important to point out that what was
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being measured in each case is the binding of the agonist ([^H]8-OH-DPAT); changes in 
the binding parameters of agonist produced by peptide can then be monitored. Figure 11 
gives an example of a Scatchard plot for [^H] 8-OH-DPAT binding in the presence of 10 
pM P9.
The Hill formulation is a method for analyzing drug saturation binding curves to 
determine whether the interaction between ligand and receptor is cooperative. It is 
important to point out again, that binding of [^H] 8-OH-DP AT is being measured. In the 
presence of 100 pM P9, shown here (Fig. 12), the slope of the line is equal to .97, which 
is very close to 1. [^H] 8-OH-DP AT binds to H5-HT1AR with a unitary binding site in a 
non-cooperative manner (Weber, 1997). P9 did not change that relationship. As with 
Scatchard analysis, Hill plots were conducted in many experiments. The results shown 
here are an example. Since all Hill plots gave coefficients of about 1, we probably did not 
gain a tremendous amount of knowledge, other than to conclude that none of the peptides 
(PI, P8, P9, P l l )  changed the nature of non-cooperative binding of [^H] 8-OH-DP AT 
with the receptor.
cAMP Determination
As seen in Figure 13, P9 did not change forskolin-stimulated cAMP formation. 5- 
HT in this case inhibits 81 % (of forskolin stimulated cAMP). The combination of 5-HT 
and P9 also was not different from 5-HT alone. This suggests that P9 is unable to activate 
the G-protein directly. P9’s actions on cAMP formation were not easy to interpret. The 
results were variable and over the series of experiments conducted over two years, the
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conclusions changed. The cAMP findings may make more sense following presentation 
of y-S-GTP incorporation experiments in the next section.
y-S-GTP Incorporation
Experiments with [^^S]y-S-GTP incorporation showed almost identical results as 
in cAMP with respect to 5-HT; that is, 5-HT increased y-S-GTP incorporation by 50% 
over control. P9 alone showed lower incorporation of y-S-GTP than the basal 
incorporation (control), a unique result. In combination with 5-HT, P9 lowered y-S-GTP 
incorporation compared to 5-HT alone. This may well represent the basal y-S-GTP 
lowering seen from P9 alone. This striking result, which was repeated multiple times has 
not been explained at this point. The result may suggest a direct modulation by P9 of the 
GTP binding site on the G-protein alpha sub-unit.
Or, P9 may be influencing a vital GTP binding regulatory element. In either case, 
the result is dramatic and significant. The result could be consistent with the cAMP data. 
If a peptide was inhibiting G protein function as P9 appeared to, this would probably 
show up in forskolin-stimulated experiments as a neutral effect. That is, in a negatively 
coupled system like H5HT1AR, it is difficult, perhaps unlikely, to further stimulate 
adenylyl cyclase beyond that produced by a high concentration of forskolin. If nothing 
else, a lesson learned from these studies is that various forms of measuring signal 
transduction are powerful. Although different tests may be examining similar aspects of 
signal transduction, they are not examining exactly the same thing. Possible differences 
that may arise from conducting such tests may be quite useful in learning more about the 
system.
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Hypothesis Modification
The first part of the original hypothesis seems reasonable. P9 does seem to 
represent a segment of IL3 important to coupling receptor and G protein. Since its 
activity was less than PI, the missing 5 amino acids in P9 do seem to play a role in 
forming the optimal conformation of the loop to produce coupling. The second part of the 
hypothesis needs a change. While in cAMP experiments it appears that P9 is inactive, in 
y-S-GTP incorporation, P9 is active, in a negative sense. Whether such activity represents 
the native receptor region’s actions, is not known. The second part of the hypothesis 
changes to: P9 represents a segment of the native loop 3 responsible for regulation of 
GTP binding to the G protein’s alpha subunit.
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Figure 10
DISPLACEMENT OF (’H)-8-0H DPAT BY PEPTIDE P9 IN MEMBRANE
PREPARATIONS OF THE H5HT1AR
Results shown are mean +/- SEM, with n’s of 2-5. Experimental conditions are outlined in Methods. 
Summary results for P9 are shown in Table IV.
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Figure 11
C O N C EN TR A TIO N -D EPEN D EN C Y  OF SPECIFIC [^H]8-OH-DPAT BINDING  IN THE  
PR ESEN CE OF P9 IN M EM BRA NE PR EPAR ATIO N S OF H5HT1AR.
X-axis: Inverse concentration o f the ligand, 8-OH-DP AT in 1/nmol/1. Thus, 1 corresponds to 1 nmol/1
whereas 5 corresponds to 0.2 nmol/1. Y-axis: LR is the concentration of the ligand-receptor complex; LR 
max determined by Scatchard analysis. The axis was originally plotted as the dimensionless ratio: 1/LR/LR 
max. The lower line ( ♦ - ♦ )  is control [^H] 8-OH-DP AT binding in the absence of P9. The middle line (□ Ql 
is [^H]8-OH-DPAT binding in the presence of 10'  ̂P9. The upper line (A-A) is [^H]8-0H-DPAT binding in 
the presence of 10 P9. All experiments were completely run at least twice in triplicate. Correlation
coefficients for the lines are all above 0.99 Experimental conditions are outlined in Methods.
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Figure 12
SCATCHARD ANALYSIS OF [̂ H] 8 - O H -  DPAT BINDING IN 5HT1AR 
MEMBRANES IN THE PRESENCE OF 10'® M P9 IN H5HT1AR MEMBRANES
The x-axis is picomolar. The Ky for [’H] 8 -  OH -  DPAT is about 1.3 nM. Bmax is about 16 pM. Other
experimental conditions are outlined in Methods.
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Figure 13
HILL ANALYSIS OF FH] 8-OH-DPAT BINDING IN 5HT1AR MEMBRANES IN
THE PRESENCE OF 10 “ M P9
Results are from a specific experiment in which points were gathered in triplicate (L) in the free 
concentration of [^H] 8-OH-DPAT. (LR) is the concentration of the [^H] 8-OH-DPAT/H5HT1AR 
complex. [LRJmax was determined from Scatchard Analysis. Other experimental conditions are outlined in 
Methods.
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Figure 14
INHIBITION OF FORSKOLIN-STIMULATED cAMP ACCUMULATION OF 
5HT AND PEPTIDE P9 IN WHOLE CELL PREPARATIONS OF THE HUMAN
5HT1A RECEPTOR.
Results are mean +/- SEM from 3 experiments run in duplicate or triplicate. Values are expressed as 
percent of forskolin (FSK)-stimulated cAMP. All conditions contained forskolin (30 pmol/L). 5-HT 
concentration was 10 pmoI/L. P9 concentration was 0.1 mmol/1. Other experimental conditions are outlined 
in Methods. Summary results for P9 are shown in Table IV.
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Figure 15
[^®S]y-S-GTP INCORPORATION INTO H5HT1AR MEMBRANES
BY 5HT AND P9
Results are mean +/- SEM of 2 experiments, all run in triplicate. Values are expressed as percent of 
S-GTP incorporated in controls (basal) lacking 5HT or P9. [^^S]y-S-GTP concentration in all conditions 
was 0.1 nmol/1. 5HT concentration was 1 pmol/L. P9 concentration was 0.1 mmol/1. *P9 significantly 
different from control (p<0.01). Other experimental conditions are outlined in Methods.
Peptide PI
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Hypothesis
PI represents a segment of native IL3 responsible for coupling to and activation 
of receptor. As a synthetic, isolated peptide, PI shows non-competitive binding and can 
activate G protein on its own.
Sequence
IFRAARFRIRKTVKK
Introduction
PI is the parent peptide from which all the other IL3 peptides were derived and 
compared. Most of the work on the peptide was carried out by other students (Hayataka 
et al., 1998). Work with PI constitutes a small but important part of this thesis, necessary 
because experiments using a range of agonist concentrations large enough to yield 
inversion analysis as well as y-S-GTP incorporation had not been conducted in the earlier 
investigations. Doing these experiments in the current series of studies allowed a more 
complete understanding of PI while providing critical comparisons with the principal 
peptides of the thesis.
Agonist Inhibition/Concentration-Dependencv
Figure 15 indicates the concentration-dependency of specific [^H] 8-OH-DPAT 
binding in the presence of two concentrations of PI (1 and 10 pM) in membrane 
preparations of H5-HT1AR. The result from the inversion plots is unique from the other 
peptides and in fact shows dual characteristics of inhibition. From these lines that have
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different slopes we speculate that PI shows “mixed inhibition” with a trend towards 
uncompetitive inhibition. There is more than a suggestion of competitive binding in this 
graph. Thus, of all the peptides studied, there is a greater chance with P 1 that at least part 
of its activity is due to competition with agonist at the receptor’s ligand binding-site.
y-S-GTP Incorporation
Figure 16 presents the results from [^^S]y-S-GTP incorporation assays in 
membrane preparations of H5-HT1AR. PI, much like P8 incorporated about 30% y-S- 
GTP above control. This signal was not as strong as 5-HT’s 60 % incorporation over 
basal levels, but it does show that PI behaves similarly to P8 (which has three additional 
amino acids at the N-terminal) with respect to y-S-GTP incorporation. Most importantly 
it does point out that PI has an effect on its own. These results are consistent with those 
that Hayataka et al. (1998) found with cAMP, in which PI gave a small but significant 
direct stimulation of G,.
Hvpothesis Modification
The original hypothesis is accepted with one substantial caveat. PI may be 
binding to the receptor’s ligand binding-site. This is a serious uncertainty as perhaps the 
greatest concern with any of these peptides concerns their site of binding, particularly if 
one of the sites of binding is the ligand binding-site. PI, although the parent peptide, may 
not be the most useful experiment tool.
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Figure 16
C O N C EN TR A TIO N  D EPEN DEN C Y  OF SPECIFIC [^H)8-OH-DPAT BIND ING  IN THE
PR ESENCE OF PI IN M EM BRA NE PR EPA R A TIO N S OF H5HT1AR.
X-axis: Inverse concentration of the ligand, [^H]8-OH-DPAT in 1/nmol/L. Thus, 1 corresponds to 1 nmol/1 
whereas 5 corresponds to 0.2 nmol/1. Y-axis: LR is the concentration of the ligand-receptor complex; LR 
max determined by Scatchard analysis. The axis was originally plotted as the dimensionless ratio: 1/LR/LR 
max. The lower line ( ♦- ♦ )  is control [^H]8-OH-DPAT binding in the absence o f PI. The middle line (□ g 
is [^H]8-OH-DPAT binding in the presence of PI (10-6M). The upper line (A-A) is [^H]8-OH-DPAT 
binding in the presence of PI (4 X 10-6M). Correlation coefficient for upper line 0.97; correlation 
coefficients for middle and lower lines exceed 0.99. All experiments were completely run at least twice in 
triplicate. Other experimental conditions are outlined in Methods.
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Figure 17
[^®S)y-S-GTP INCORPORATION INTO H5HT1 AR MEMBRANES BY
5HT AND PI.
Results are mean +/- SEM of 2 experiments, all run in triplicate. Values are expressed as percent of [^^S]y- 
S-GTP incorporated in controls (basal) lacking 5HT or PI. [^^S]y-S-GTP concentration in all conditions 
was 0.1 nmol/I. 5HT concentration was 0.1 pmol/L /I. PI concentration was 1 pmol/L /I. *P1 significantly 
different from control (p<0.05). Other experimental conditions are outlined in Methods.
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Peptide P li
Sequence
lALDRYWAITD
Hypothesis
PI 1 represents a region of H5-HT1AR responsible for coupling to and activation 
of the cognate G protein
Introduction
The work on peptide PI 1 was actually the continuation of the work done by Tom Ortiz 
(Ortiz et al., 2002) a graduate student in the Department of Pharmaceutical Sciences. An 
important point to note here is that PI 1 is a peptide from the transmembrane 3 (TM3)/ 
intracellular loop 2 (IL2) region of H5-HT1AR. The work on P ll  was prompted by a 
number of considerations. First, the preliminary data from P ll  suggested that the peptide 
uncoupled receptor from G protein (see Table 5, Fig. 17; this thesis) but lacked further 
activity. Second, we wished to complement existing data from signal transduction 
experiments by utilizing y-S-GTP incorporation assays. Third, the existing data with 
agonist inhibition assays required some completion by varying agonist concentrations such 
that full-scale inversion analysis could be conducted. Fourth, n’s for the cAMP experiments 
needed expansion. In the results reported below for Pl l ,  P l l  is also compared with P7, a 
weakly active but previously unreported peptide (Ortiz et al., 2002)
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Agonist Inhibition/Concentration-Dependencv
Peptide P l l  produced concentration-dependent effects as measured by agonist 
inhibition; these changes were seen whether determined in whole cell, crude membrane, 
or solubilized receptor preparations. The agonist inhibition results are summarized in 
Table V (Ortiz et al, 2002). These results have been previously reported but are presented 
here to provide the context for new findings that are to follow. Agonist inhibition is a 
procedure based upon the receptor’s affinity state; when the receptor is G protein 
coupled, it is in the high affinity state. When the receptor is uncoupled from the G 
protein, it is in the low affinity state. Thus, if a peptide uncouples G protein and receptor 
in a concentration-dependent fashion, then the effect is represented by a dose-response 
inhibition curve (Maguire et al., 1976; Peroutka et al., 1979; Hayataka, 1998; Ortiz, 
2000). By inference, the uncoupling actions of P ll  reported here imply the ability of the 
N-terminal region of the native 12 loop to couple with G protein.
For comparative purposes in membrane preparations, the agonist inhibition effects 
of P7, a truncated version of PI, a native 15 MER (Hayataka, 1998) from the TM5/IL3 
interface, are given in Figure 17 along with the activity of Pl l .  In these membrane 
preparations, P7 was barely active in comparison to P l l  or P7’s parent PI; the same 
generalization holds with respect to whole cell and solubilized preparations. We have not 
conducted structure-activity studies with P ll  analogues. However, it is important to 
contrast the biology of any active peptide with an inactive or minimally active “control.” 
For that reason, P7 is reported at this time.
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There is concern with any of these peptides regarding their ability to reach the 
putative site of action at the receptor/G protein interface. The large difference in IC50’s 
for PI 1 in different receptor preparations suggest the possibility of reduced access to the 
interface when the peptide must penetrate the membrane barrier. Peptide P ll  has been 
analyzed in all three receptor preparations in the agonist inhibition format (Table V). 
Solubilized receptors were most sensitive, followed by whole cells and membranes. 
Since P l l  was about 3-8 times more active against solubilized receptors compared to the 
membrane and whole cell receptor preparations, it is possible that the peptide has 
somewhat better access to the receptor/G protein interface in the solubilized setting. This 
pattern of activity is similar to that seen with PI, the native peptide from the TM5/IL3 
interface, studied in earlier work (Ortiz, 2000). On the other hand, P7 had minimal 
agonist inhibition activity in all receptor preparations (see Table V for P7). These 
activities were so weak that IC 50’s could not be determined at the concentrations tested 
(limited by peptide solubility); thus, maximal inhibitions at 10'"* mol/1 are given in Table 
V for P7, rather than IC 50’s. Thus, for a peptide like P7, it is difficult to know if it has 
trouble reaching the putative intracellular site of action since complete concentration- 
dependency information is unavailable in this experimental format. Nevertheless, it is 
important to emphasize the conclusion that active peptides studied by the methods used 
here show distinctively different quantitative and qualitative concentration-effect 
relationships relative to inactive peptides.
One of the great concerns for a peptide used in any system is its specificity. We 
have suggested specificity parameters for PI and its derivatives at TM5/IL3 using a
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variety of controls (Hayataka, 1998; Ortiz, 2000). We believe that the data shown in 
Figure 18 provides strong evidence for the action of P ll  at the TM3/IL2 interface rather 
than another site such as the ligand binding-site. In this concentration-dependent analysis, 
if PI 1 were acting at the ligand binding- site, then it would competitively interfere with 
[^H]-8-OH-DPAT binding. If P ll  were acting at some allosteric site on the receptor 
complex, then the plot would show non-competitive interactions. Rather the plot is 
uncompetitive, exactly what would be expected if the site of interaction is between 
receptor and G protein. Another way of looking at this is that parallel inhibition lines like 
those seen in this graph represent interaction of inhibitor with the agonist/receptor 
complex itself rather than competing for agonist at the ligand binding-site or binding to 
an allosteric site. Final resolution of specificity and site(s) of action will require high- 
resolution spectral studies as mentioned in the conclusion of the thesis.
cAMP Determination
When P l l  was analyzed for biological activity in whole cell preparations utilizing 
measurement of forskolin-stimulated intracellular cAMP concentrations, it was inactive, 
either alone or in combination with 5-HT (Fig. 19; also see Table V). For reference, this 
negative result is in contrast to the parent peptide from IL3, peptide PI, which stimulated 
G protein directly at micromolar concentrations(Weber, 1997). In fact many of P i ’s 
substitution derivatives (Ortiz, 1999) also stimulated G protein, some of them better than 
PI. The results for P l l  from the IL2 loop imply a distinct differentiation between 
uncoupling actions (agonist inhibition) and lack of G protein activation (decreases in 
cAMP concentration in this negatively coupled system).
49
y-S-GTP Incorporation
P ll  was ineffective at stimulating incorporation of [^^S]y-S-GTP above 
background levels (Fig. 20; also see Table V). These results are consistent with the 
inactivity of P ll  in G protein activation as shown via cAMP formation (Fig. 19). 
Additionally, P l l  did not interfere with 5-HT’s ability to stimulate GTP incorporation, 
indicating that P l l ,  as previously shown in Figure 18, does not competitively interact 
with 5-HT at the receptor’s ligand binding site. These results are again consistent, in 
conjunction with the agonist inhibition results, with a peptide that represents a portion of 
the native receptor that is responsible for coupling to G protein, but not activating it.
Peptide ICso (pmol/L)*
% Inhibition 
of Forskolin 
Stimulated 
cAMP*
% Change in 
y-S-GTP 
Incorporation®
Whole Cell M em brane Solubilized
P l l \ 6 ± 2 1 ± \ 2 ±  0.5 1 3 ± 8 0 ± 3
P7 ND 25 ±  1 49 ± 8 0 ND
TABLE V: SUMMARY OF RESULTS FOR PEPTIDE PI 1 FROM THE TM3/IL2 
REGION AND TRUNCATED PEPTIDE P7 FROM THE TM5/IL3 REGION OF THE
HUMAN 5-HTlA RECEPTOR
Whole cell, membrane, and solubilized indicate the preparation of receptor in which the IC50 
was determined; n ’s = 3-5 unique preparations in each case. Results for P7 are maximum percent 
inhibition at 10^ M rather than IC50 values. ^Expressed as percent inhibition relative to controls 
treated with 30 pmol/L forskolin (FSK). ^Expressed as percent of background incorporation. 
ND: experiments not done for this condition.
50
Hypothesis Modification
Since P l l  is active as measured by uncoupling but inactive in further bioassays, 
the hypothesis must be rejected and modified as indicated below. The results presented 
here for P l l  corroborate and extend previous work with 7TMDR (Dohlman et al, 1991; 
Savarese & Fraser, 1992; Baldwin, 1994; Strader et al,  1994; Varrault, 1994). While 
many members of this superfamily utilize the 12 loop in G protein interactions, there is 
much to be known about the specific determinants of coupling and G protein activation. 
Since P l l  is similarly active to the IL3 peptide PI in the agonist inhibition format, we 
suggest that P l l  uncouples receptor from G protein in an analogous fashion to that 
previously observed for PI.
P l l ,  however, does not show activity in the signal transduction system as judged 
by its inability to decrease cAMP concentrations in the forskolin-stimulated format nor in 
its inability to stimulate G protein incorporation of y-S-GTP. As PI is a mimic of the 
receptor’s IL3 N-terminus, and P ll  is a mimic of the receptor’s IL2 N-terminus, we 
reach the following conclusion: in the H5-HT1A receptor, the N-termini of both 
intracellular loop 2 and loop 3 are involved in receptor-G protein coupling; only the N- 
terminus of IL3, though, is further implicated in G protein activation. In previous work 
with the 5-HTlAR, (Varrault, 1994 ) demonstrated that the C-terminal section of IL3 is 
involved in G protein coupling and activation. Further, they showed that the entirety of 
IL2 produces G protein coupling and activation. The results from our study extend this 
observation by establishing that the N-terminal region of IL2 is specialized for coupling
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but is not involved in activation; this is our current working hypothesis. Since the IL2 
peptide P l l  reported here has potential as a probe of the receptor/G protein interface due 
to its differential effects, it could be a powerful tool in exploring the interface with 
techniques such as multi-dimensional NMR (Burritt et al., 1998).
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Figure 18
DISPLACEMENT OF SPECIFICALLY-BOUND [^H]8-OH-DPAT
in membrane preparations by the TM3/i2 H5HTI AR peptide probe, P l l  (A-A), and the TM5/i3 H5HT1 AR 
peptide probe, P7 (0 -0 ). Experimental conditions are outlined in Methods. Results shown are means +/- 
SEM, with n ’s o f 2-5. Summary results for P7 and P l l  are found in Table V.
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Figure 19
CONCENTRATION-DEPENDENCY OF SPECIFIC [^H]8-OH-DPAT BINDING IN THE 
PRESENCE OF P ll  IN MEMBRANE PREPARATIONS OF H5HT1AR.
X-axis: Inverse concentration of the ligand, [^H]8-OH-DPAT in 1/nmol/L. Thus, 1 corresponds to 1 nmol/L 
whereas 5 corresponds to 0.2 nmol/L. Y-axis: LR is the concentration of the ligand-receptor complex; LR 
max determined by Scatchard analysis. The axis was originally plotted as the dimensionless ratio: 1/LR/LR 
max. The lower line ( ♦ - ♦ )  is control [^H]8-OH-DPAT binding in the absence of P l l .  The middle line ( B 
Q is [^H]8-OH-DPAT binding in the presence of 2 pmol/L Pll. The upper line (A-A) is 8-OH-DPAT 
binding in the presence of 8 pmol/L PI 1. All experiments were completely run at least twice in triplicate. 
Correlation coefficients for the lines, top to bottom are: 0.880; 0.990; 0.994. Experimental conditions are 
outlined in Methods.
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Figure 20
INHIBITION OF FORSKOLIN-STIMULATED cAMP ACCUMULATION BY
5HTAND Pl l .
Results are mean +/- SEM from 5 experiments run in duplicate or triplicate. Values are expressed as 
percent of forskolin-stimulated cAMP. All conditions contained forskolin (30 pmol/L). 5-HT concentration 
was 10 pmol/L. PI 1 concentration was 0.1 mmol/1. Other experimental conditions are outlined in Methods. 
Summary results for P l l  are shown in Table V.
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Figure 21
I^*Sly-S-GTP INCORPORATION INTO H5HT1AR MEMBRANES
BY 5HT AND P l l .
Results are mean +/- SEM of 2 experiments, all run in triplicate. Values are expressed as percent of [^^S]y- 
S-GTP incorporated in controls (basal) lacking 5HT or P l l .  [^^S]y-S-GTP concentration in all conditions 
was 0.1 nmol/L. 5HT concentration was 1 pmol/L. P l l  concentration was 0.1 mmol/L. Other experimental 
conditions are outlined in methods. Summary results for PI 1 are shown in Table V.
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Dipropyltryptamine (DPT)
Hypothesis
DPT is an agonist at the H5-HTÎAR
Introduction
Dipropyltryptamine (DPT) is a synthetic drug (Shulgin, 1969; Soskin, 1975) that 
was studied briefly in the 1960’s and 70’s and then largely forgotten since identification 
of multiple serotonin (5-hydroxytryptamine; 5-HT) receptor (R) subtypes (Barnes, 1999). 
DPT has been virtually unknown in the scientific literature since the mid- 1970’s when its 
use as an adjunct to psychotherapy faded. DPT is structurally related to the better known 
dimethyltryptamine (DMT), a potent hallucinogen (Barker et al., 1981; Pierce, 1989; 
Glennon, 1992; Deliganis, 1999). The studies reported here represent the initial 
characterization of dipropyltryptamine at cloned H5-HT1AR (Arthur et al., 1993; 
Hayataka, 1998; Ortiz, 1999; Cowen, 2000) and to a lesser degree cloned rat 5-HT2AR 
(Baldwin, 1994).
Both H5-HT1AR and rat 5-HT2AR is seven transmembrane domain (7TMD), G- 
protein coupled (GPC) receptors, and both have been linked to biomedical conditions 
such as depression, anxiety, and migraine headache. Since H5-HT1AR is negatively 
coupled to the adenylyl cyclase signal transduction system via Gi, functional attributes of 
ligands that bind to the receptor can be monitored by quantification of intracellular cyclic 
AMP (cAMP).
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Additionally, since both H5-HT1AR and rat 5-HT2AR are GPCR, receptor 
activity can be followed by GTP incorporation techniques. Results reported here suggest 
that DPT is a high affinity partial agonist at H5-HT1AR and a lower affinity agonist at 
rat 5-HT2AR. These conclusions have implications for use of DPT or structural 
analogues at the ligand binding site of H5-HT1AR (Blair et al., 2000). The primary 
reason for presenting DPT’s activity in the context of this thesis is to provide comparison 
and contrast to the effects of peptides PI, P8, P9 and P ll  at 5-HTlAR. Whereas the 
peptides are, in general, not competitive ligands at the H5-HT1AR ligand-binding site, 
DPT, which is competitive provides a clear contrast.
Displacement of l^HIS-OH-DPAT from H5-HT1AR
DPT was synthesized by Dr. Chuck Thompson at the University of Montana (Fig 
21). The first series of experiments were designed to determine the affinity of DPT at 
membrane preparations of 5-HTlAR. Figure 22 shows that DPT produced excellent 
concentration-dependent effects as measured by inhibition of specific agonist [^H]8-OH- 
DPAT binding at H5-HT1AR. The displacement of [^H]8-OH-DPAT at H5-HT1AR 
indicates that DPT has moderately high affinity with an apparent IC50 of about 0.1 pM.
In Figure 23 two different concentrations of DPT (40 nM and 200 nM) were 
compared with a control lacking DPT against various concentrations of [^H] 8-OH-DPAT 
bound to H5-HT1AR. In this adaptation of the Lineweaver-Burke plot of enzyme 
kinetics, both agonist [^H]8-OH-DPAT concentrations (x-axis) and agonist-receptor 
complex concentrations (y-axis) are inverted. The resulting straight lines allow estimation
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of the nature of DPT/ agonist interactions. Interpretation of the experiments analyzed 
here is consistent with DPT inhibiting agonist binding competitively.
cAMP Determination
DPT’s ability to bind at the H5-HT1AR raised the question of its potential to 
trigger the signal transduction system. Determination of intracellular cAMP 
concentrations tests the hypothesis that DPT is an agonist. Fig 24 suggests that DPT 
reduced forskolin-stimulated cAMP concentrations. However, this agonist-like effect is 
not significant. In combination with 5-HT, DPT diminished the effect observed with 5- 
HT alone. This is consistent with the conclusion that DPT is an antagonist. These results 
lead to apparent rejection of the original hypothesis that DPT is an agonist at this 
receptor.
y-S-GTP Incorporation
Figure 25 summarizes another approach to testing DPT’s capacity to trigger 
signal transduction at H5-HT1 AR. As anticipated, 5-HT by itself incorporated 92 % more 
than the basal incorporation of [^^S]y-S-GTP (buffer). Additionally, DPT showed 
significant concentration-dependent incorporation of [^^S]y-S-GTP, though the amount of 
incorporation is not as much as that of 5-HT itself. When 5-HT and DPT were 
administered together, the effect of 5-HT alone was reduced by DPT. Together, DPT and 
5-HT were not able to exceed the effect of 5-HT alone or to even equal the 5-HT effect 
alone. This would indicate that DPT acts as an antagonist. With DPT producing weak 
agonist effects alone, but acting as an antagonist in the presence of agonist (5-HT), it is
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proposed that the original hypothesis that DPT is an agonist be rejected. The modified 
hypothesis is that DPT is a partial agonist at H5-HT1AR. The puzzling results with 
cAMP may have been heading in this direction but require more experiments for a 
complete test.
DPT at the Rat 5-HT2a Receptor
For the sake of completeness, preliminary results for DPT’s interactions at the rat 5- 
HT2a receptor will be reported. When [^H]Ketanserin is bound to the receptor, DPT 
displaced the ligand in a concentration-dependent manner. The apparent affinity is lower 
than that reported at H5-HT1AR, however, as the IC50 is 200 times higher. In signal 
transduction assays with [^^S]y-S-GTP incorporation, DPT showed activity consistent with 
that of an agonist. Thus, the working hypothesis is that DPT is a low affinity agonist at rat 
5-HT2AR. Whether the differences reported here for 5-HT 1A and 5-HT2A receptors are 
species related is unknown at this time.
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Figure 22
SYNTHESIS OF N,N-DI-A^-PROPYLTRYPTAMINE
Tryptamine (1.6 g; 10 mmol) and diisopropylethylamine (1.04 ml; 60 mmol) were dissolved in diethyl 
ether (60 ml) at 0 °C. 1-Iodopropane (1.02 g; 0.6 ml; 60 mmol) was added dropwise with stirring over 1 h. 
The reaction was stirred 16 h at room temperature, filtered to remove salts, and evaporated to an oil. The 
crude product, which was contaminated with N-propyltryptamine and some unreacted tryptamine, was 
chromatographed on silica gel to afford the product, N,N-di-n-propyltryptamine in 46% yield. The purified 
product had elemental and spectral characteristics consistent with literature values.
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Figure 23
INHIBITION OF [^H]8-OH-DPAT BINDING BY DIPROPYLTRYPTAMINE 
(DPT) IN MEMBRANE PREPARATIONS EXPRESSING THE HUMAN 5-HTlA
RECEPTOR (H5-HT1 AR).
Results are mean +/- SEM with n ’s of 2-5. Other experimental conditions are outlined in Methods.
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Figure 24
CONCENTRATION-DEPENDENCY OF |’H] 8-OH-DPAT BINDING IN THE 
PRESENCE OF DIPROPYLTRYPTAMINE (DPT) IN MEMBRANE 
PREPARATIONS OF THE HUMAN 5HT1A RECEPTOR (H5HT1AR).
Correlation coefficients exceed 0.99 for the lower two lines; correlation coefficient for the upper line is 
0.89. Additional experimental conditions are described in Methods. [L] is [^H]8-OH-DPAT. On the x-axis 
1 = InM; 5 = 0.2nM., etc. On the y-axis [LR] is the concentration of the [^H]8-0H-DPAT-H5HT1AR 
complex.
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Figure 25
EFFECTS OF SEROTONIN (5HT) AND DIPROPYLTRYPTAMINE (DPT) ON 
FORSKOLIN-STIMULATED CYCLIC AMP (cAMP) FORMATION IN WHOLE 
CELL PREPARATIONS OF THE HUMAN 5-HTlA RECEPTOR (H5-HT1AR).
All conditions contain forskolin (30 pM). Additional experimental conditions are described in Methods. 
DPT conc. is 0.1 pM in all cases.
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Figure 26
EFFECTS OF SEROTONIN (5HT) AND DIPROPYLTRYPTAMINE (DPT) ON 
INCORPORATION OF (” S]y-S-GTF INTO MEMBRANE PREPARATIONS OF 
THE HUMAN 5-HTlA RECEPTOR (HS-HTIAR).
Basal represents incorporation in the control setting (buffer). *DPT (10-7M) significantly different from 
control (p<0.05); **DPT (10-6M) significantly different from control (p<0.02). Additional experimental 
conditions are described in Methods. 5-HT conc. is_0.1 pM in all cases.
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CONCLUSIONS
The various peptides studied during the course of this project narrate a very 
multifaceted, but subtle story about the H5-HTIAR/G-protein interface. Many of the 
peptides showed reproducible activity at the receptor. An important point, which should 
be emphasized, is that P8 and P9 were the focal peptides in this project. Mini-projects 
performed new types of experiments with P 1 and P 11 to help better understand 
knowledge previously learned .about these peptides. P7, a largely inactive peptide, has 
been included to contrast the activities of the other peptides, and finally, 
dipropyltryptamine (DPT) has been studied and analyzed here to compare an agent, DPT, 
active at the receptor’s ligand binding-site with agents that putatively act at the 
receptor/G protein interface.
To put these results in perspective, we shall compare the peptides as we have 
done with the actual methodology; i.e. Agonist Inhibition/Concentration-Dependency and 
Signal Transduction (cAMP determinations; and y-S-GTP incorporation). Finally, the 
context of these studies with other knowledge about 5-HTR’s and other GPCR’s will be 
discussed, as well as future projections for this approach beyond the current thesis.
Agonist Inhibition/Concentration-Dependency
Which Positions in the Peptides are Critical to G Protein Coupling?
P8 vs. PI: The IC50’s as well as the concentration-dependency curves of P8 (this 
thesis) and PI (Hayataka et al., 1998) indicate that they behave in a similar manner; this
6 6
may seem obvious; P8 and PI are structurally very similar, with P8 having an additional 
three amino acids at the N-terminal end. This could well suggest that the increased size 
(of P8), extending into TM5, does not affect agonist inhibition, and by inference, 
coupling of the native loop and G protein, in any significant manner. While this similarity 
may seem given at this point, it was by no means understood prior to the experiments, 
and the structural difference needed to be tested.
P9 vs. PI: The results for P9, which is PI minus the first five N-terminal amino 
acids, indicated that P9 (this thesis) has lower agonist inhibition activity relative to PI 
(Hayataka et al, 1998). Depending on receptor preparation being analyzed, P9 is 8 to 60 
times less effective than PI. This corroborates, to an extent, the general observation with 
the panel of peptides already studied, that truncates of PI have low activity or are 
inactive. Previous work by Ortiz et al. (2000) concluded that positions 6-9 of PI (the first 
4 positions of P9’s N-terminus) are most critical to receptor/G protein coupling, and that 
the next 6 positions toward PTs C-terminus were necessary but not as critical. The P9 
sequence is these exact 10 amino acids. Thus, studying P9 gave a stiff, if not completely 
stringent, test of Ortiz’ hypothesis. The additional conclusions garnered from studying 
P9, however, are that the first five N-terminal amino acids of PI are not irrelevant to 
coupling activity of ÏL3. Thus, the entirety of PI seems to be active in coupling. The role 
of positions to the C-terminal side of PI remains to be tested.
P7 vs. PI: P7 (this thesis) fits into this picture. It is the first 9 positions of PI. 
Using the theme of truncating to the N-and C-terminal sides of critical residues 6-9, P7
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“completes’* the picture started with P9. For all intents and purposes, P7 is inactive. It is 
not only too small, but it lacks the important residues to the C-terminal side of position 9. 
Even though P7 retains key residues 6-9 of PI, the loss of positions 10-15 is too great. 
While truncating positions 1-5 in P9 markedly reduced activity, it did not eliminate 
activity. Loss of positions 10-15 in P7 virtually eliminated activity. It seems that the 
amino acids to the C-terminal side of positions 6-9 are more important than the positions 
to the N-terminal side of positions 6-9.
PI 1: Though derived from an entirely different loop (12), PI 1 has substantial 
agonist inhibition characteristics. PI 1 produced inhibition in the micromolar range in all 
receptor preparations. By inference this action represents the ability of the N-terminal 
region of the native 12 loop to couple with G-protein. The results corroborate and extend 
previous work with 7TMDR (Dohlman et al., 1991; Savarese & Fraser, 1992; Baldwin, 
1994; Strader et a i, 1994; Varrault, 1994). While many members of this superfamily 
utilize the 12 loop in G-Protein interactions, there is much to be known about the specific 
determinants of coupling. From the results reported here, it seems that the first 11 
positions of IL2 adjacent to TM3 are essential for IL2/G protein coupling. Although P ll  
and PI are from different receptor loops, their activities in agonist inhibition are close (PI 
is slightly more active). Seemingly, the N-terminal segments of both IL2 and IL3 are 
critical to receptor/G protein coupling.
6 8
What is the Mechanism o f  Peptide Uncoupling Activity?
Dipropyltryptamine (DPT) as a Reference: DPT actiyity in the adaptation of 
Lineweayer- Burke analysis (Fig. 23) strongly suggested that [^H]8-OH-DPAT and DPT 
compete for the same binding site. Since [^H]8-OH-DPAT is known to haye highly 
specific binding to the ligand binding-site of 5-HTlAR, DPT must be considered a 
specific 5-HTlAR-ligand binding-site agent. While this observation is interesting in its 
own right, it is irreleyant to this thesis except for the assumption that the peptides are not 
binding to the ligand-binding site. Therefore, DPT’s pharmacology is presented as the 
contrast to what the peptides should not be.
P l l : P H ’s actiyity in the adaptation of Lineweayer-Burke analysis suggested an 
uncompetitiye mechanism. This result starkly contrasts with DPT’s actiyity. It is difficult 
to conclude other than that P l l  does not interact at the H5-HT1AR ligand-binding site. 
The site of interaction remains unknown, but the uncompetitiye mechanism giyes support 
to the conclusion that the peptide binds between receptor and G protein.
PI. P8. and P9: P8 and P9 show non-competitiye inhibition characteristics. PI 
also shows uncompetitiye properties at higher concentrations; this is interesting because 
P8, its yery close relatiye, also seems to show such tendencies. Oyerall, though, PI has 
“mixed” interaction properties with an apparent component of competitiye inhibition. 
The purpose of studying these peptides is to better understand their biology. The 
information summarized in this section contributes to this adyancement. Eyen more
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important, though, is the application of this biology in evaluating the long-term potential 
of these peptides as probes of the H5-HT1AR/G protein interface. P l l ,  P8, and P9, all 
possessing non-competitive or un-competitive mechanisms, should be useful tools for 
helping probe the native receptor/G protein structure. PI is suspect if it is partially or 
completely active at the ligand binding-site.
Signal Transduction
Do the Peptides Directly Activate G Proteins?
PI. P8. and P9: A preliminary answer to this question for PI was available from 
previous cAMP determinations (Hayataka, 1998). PI is weakly active in decreasing 
cAMP in this negatively coupled system. This conclusion is fortified by addition of the y- 
S-GTP incorporation experiments of this thesis. PI increased y-S-GTP incorporation 30% 
above basal levels of incorporation. Therefore, the answer is positive to this question. PI 
has the capacity to directly stimulate G proteins.
PI and P8 produce analogous results in signal-transduction experiments. This is 
especially true with y-S-GTP assays where the PI and P8 results were identical. The 
cAMP assays gave similar results for the two peptides. The conclusion is that P8, like PI, 
stimulates G-protein on its own. The change in structure (with P8) involving three 
additional amino acids on the N-terminus of PI produces little, if any, effect in signaling 
properties.
One important understanding that we came to, as more and more y-S-GTP 
determinations were made, is that even though the cAMP and y-S-GTP assays often yield
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similar results, the certainty of cAMP results was often lower. The principal reason for 
this is that the signal generated in y-S-GTP assays is larger and more consistent than the 
signal generated in cAMP assays. The bottom line is that greater confidence in 
conclusions is produced by y-S-GTP results.
The uncertainty of cAMP results is illustrated with P9, where the peptide does not 
significantly change cAMP levels. This conclusion masks the underlying variability of 
results, however. In multiple experiments over two years, there were instances where 
cAMP didn’t change, where it went up, and where it went down. P9 represents the most 
extreme example of uncertainty with cAMP and these peptides, but a level of unusual 
uncertainty is there for all the peptides.
Though the results from y-S-GTP incorporation typically paralleled cAMP results, 
there was a unique result with P9. The result from P9, which represents the truncated end 
of the N-terminal end of IL3, suggests that the N-terminal end could not only be 
responsible for coupling of G-protein but also de-activation.
To keep the signal transduction properties in perspective, it is important to 
emphasize that none of the peptides or DPT produced effects comparable to that of the 
neurotransmitter 5-HT. That is, in terms of both potency and effectiveness of the various 
agents, 5HT was the best, and everything else fell somewhere below its benchmark 
actions.
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Pl l :  could be considered as a peptide that did not have any activity in the signal- 
transduction system; this held true for P H ’s effects on incorporation of y-S-GTP as well 
as the effects in the adenylyl cyclase/cAMP system. As PI 1 is a mimic of the receptor’s 
IL2 N-terminus and PI is a mimic of the receptor’s IL3 N-terminus, we can now 
conclude that though both IL2 and IL3 are involved in coupling with G-Protein, only IL3 
is involved in G-protein activation. Our study corroborates the results from (Varrault) 
where it was shown that IL2 was involved in receptor coupling and activation. Varrault’s 
study did not distinguish between loop sub-regions, however. We can now add to their 
observation by stating that the N-terminal of IL2 is involved in coupling only and does 
not mediate any activation.
Future Work
The studies with PI, P8, P9, and P l l  described in this thesis have substantially 
contributed to the long-range goals of structural determination at the human 5HT1A 
receptor/G protein interface. Hayataka’s initial work with PI established the feasibility of 
working with an IL3 peptide as a biochemical probe of the interface. Ortiz’s studies with 
substitution (such as P2 and P3) and truncation (such as P6) derivatives of PI 
demonstrated potentially useful differential biochemical properties of the new probes. 
These studies provided the background to develop further hypotheses about peptide 
length and sequence that were tested with P8 and P9 in this thesis work.
The combined studies of this thesis with the developmental experiments by Ortiz 
with P l l  created a feasible tool for analysis of IL2. As has been discussed earlier, the 
various biochemical parameters now known for these peptides suggest that some of the
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peptides will be more useful than others in future studies. Envisioned future studies 
include cross-linking selected peptides to purified G proteins; and utilization of selected 
peptides to interact with purified G proteins in the context of multi-dimensional NMR 
and other high-resolution analyses. All of these experimental approaches will be designed 
to give discrete information about the binding of the peptides to G protein sites. By 
analogy, then, the high-resolution information gained from these experiments will be 
used to model receptor loop interactions with G proteins in the native state. Since the 
peptides are incomplete representatives of the native situation, they are imperfect tools. 
However, it is expected that the encouraging properties discovered in this thesis work 
indicate that these peptides have the potential to contribute to the developing 
understanding of this receptor system.
Although not formally a part of this thesis work, one additional piece of 
experimental data done in conjunction with the planned thesis work, should be mentioned 
to better anticipate the future. Ortiz discovered that the substitution derivative of PI 
known as P3 has perhaps the best potential of any of the studied peptides to activate G 
protein as determined by cAMP determination. Figure 26 extends this conclusion by 
exploring P3’s ability to increase [^^S]y-S-GTP incorporation into G protein. The results 
suggest that the cAMP results were correct, as P3 is quite capable of stimulating GTP 
incorporation. Thus, we conclude that the following peptides will be selected as the 
probes to be used in cross-linking and NMR studies: at IL3: P3 and P9; at IL2: Pl l .  
Some of the inactive peptides such as P7 may also be useful as controls. Future structure- 
activity work with P l l  may also be done to provide differential capabilities such as those 
available with the PI derivatives.
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Figure 27
ENHANCEMENT OF GAMMA-S-GTP INCORPORATION BY PEPTIDE P3 IN 
MEMBRANE PREPARATIONS OF THE H5HT1AR.
[ S]y-S-GTP was bound to membrane preparations of H5HT1AR at a concentration of 0.1 nM. Non­
specific binding was determined in the presence of 10 pM cold y-S-GTP. Assays were conducted in 
triplicate at 30°C for 30 min., and stopped by filtration with GF/C filters. All determinations were with n = 
2. Values are expressed as percent o f [^^S]y-S-GTP incorporated in controls (basal) lacking 5HT or P3.
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SCHEMATIC DIAGRAM OF LOOP 2 AND 3 ACTIVITIES AT THE 5HT1AR/G
PROTEIN INTERFACE.
Intracellular loop 2 (ic2) connecting transmembrane (TM) segments 3 and 4, and intracellular loop 3 (ic3) 
connecting transmembrane segments 5 and 6 are pictured. Arrows symbolize portions of the loops thought 
to be involved in coupling of receptor to G protein, producing conformational changes that ultimately result 
in G protein activation. The bar represents the N-terminal region of ic2, which appears to be involved in 
coupling only. The inset from the N-terminal region of ic3 gives the sequence for PI, and segments of PI 
and the analogous receptor region thought to be responsible for coupling and activation.
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Summary
Peptides PI, P7, P8, and P9 from intracellular loop 3 of the human 5-HTlA 
receptor and P ll  from intracellular loop 2 were studied for their receptor/G protein 
uncoupling and signal transduction activation properties. P7 was inactive. P ll  was active 
in uncoupling receptor and G protein, but inactive in triggering signal transduction. PI, 
P8, and P9 were active in both the uncoupling and signal transduction realms to various 
degrees. P9, especially, demonstrated unique activity in the signal transduction system, 
namely, decreasing basal levels of [^^S]y-S-GTP incorporation, suggesting a possible 
regulatory role with respect to GTP binding to G protein. The non-peptide 
dipropyltryptamine (DPT) was also examined as a competitive ligand-binding site agent 
at H5-HT1AR. Overall, these results in combination with previous studies in this 
laboratory and evidence from other laboratories, suggests a model of the human 5HT1A 
receptor/G protein interface in which the N-terminal of intracellular loop 2 is responsible 
for coupling to but not activation of G protein. On the other hand, the N-terminal of 
intracellular loop 3 is responsible for both coupling to and activation of G protein. While 
the entire 15 amino acid stretch of loop 3 studied seems to have a role in these activities, 
there is a four amino acid stretch beginning with position 6 that is particularly vital. 
Positions 6-15 may be specifically involved in regulation of GTP incorporation into G 
protein. These ideas about H5-HT1A receptor/G protein interaction are summarized in 
Figure 27.
76
REFERENCES
Acharya, S., Saad, Y. & Kamik, S. S. (1997). Transducin-alpha C-terminal peptide
binding site consists of C-D and E- F loops of rhodopsin. J  Biol Chem 272, 6519- 
6524.
Arthur, J. M., Casanas, S. J. & Raymond, J. R. (1993). Partial agonist properties of
rauwolscine and yohimbine for the inhibition of adenylyl cyclase by recombinant 
human 5-HTlA receptors. Biochem Pharmacol 45, 2337-2341.
Baldwin, J. M. (1994). Structure and Function of Receptors Coupled to G-Proteins. 
Curr.Opin.Cell Biology 6, 180-190.
Barker, S. A., Monti, J. A. & Christian, S. T. (1981). N, N-dimethyltryptamine: an 
endogenous hallucinogen. Int Rev Neurobiol 22, 83-110.
Bames, N. M., and Sharp, T. (1999). A Review of Central 5-HT Receptors and Their 
Functions. Neuropharm 38, 1083-1152.
Bamidge, D. R., Dratz, E.A., Sunner, J., and Jesaitis, A.J. (1997). Identification of 
Transmembrane Tryptic Peptides of Rhodopsin Using MALDI-TOF Mass 
Spectroscopy. Prot.Sci. 6, 816-824.
Bikker, J. A., Trumpp-Kallmeyer, S., and Humblet, C. (1998). G-Protein Coupled
Receptors: Models, Mutagenesis, and Drug Design. J.Med.Chem 41, 2911-2927.
Blair, J. B., Kurrasch-Orbaugh, D., Marona-Lewicka, D., Cumbay, M. G., Watts, V. J., 
Barker, E. L. & Nichols, D. E. (2000). Effect of ring fluorination on the 
pharmacology of hallucinogenic tryptamines. J  Med Chem 43,4701-4710.
Bourne, H. R. (1997). How receptors talk to trimeric G proteins. Curr Opin Cell Biol 9, 
134-142.
Bowler, W. B., Gallagher, J. A. & Bilbe, G. (1998). G-protein coupled receptors in bone. 
Front Biosci 3, D769-780.
Burritt, J. B., Busse, S. C., Gizachew, D., Siemsen, D. W., Quinn, M. T., Bond, C. W., 
Dratz, E. A. & Jesaitis, A. J. (1998). Antibody imprint of a membrane protein 
surface. Phagocyte flavocytochrome b. J  Biol Chem 273, 24847-24852.
Burstein, E. S., Spalding, T. A. & Brann, M. R. (1996). Amino acid side chains that
define muscarinic receptor/G-protein coupling. Studies of the third intracellular 
loop. J  Biol Chem 271, 2882-2885.
Casey, P. (1995). Protein Lipidation in Cell Signaling. Science 268.
77
Cowen, P. J. (2000). Psychopharmacology of 5-HT(l A) receptors. Nucl Med Biol 27, 
437-439.
Deliganis, A. V., Pierce, P.A., Peroutka, S.J.,. (1999). Differential interactions of 
dimethyltryptamine (DMT) with 5-HTl and 5-HT2a receptors. Biochemical 
Pharmacology 41.
Dohlman, H. G., Thomer, J., Caron, M. G. & Lefkowitz, R. J. (1991). Model systems for 
the study of seven-transmembrane-segment receptors. Annu Rev Biochem 60, 
653-688.
Dratz, E. A., Furstenau, I.E., Lambert, C.G., Thireault, D.L., Rarick, H., Schepers, T.,
Pakhlevaniants, S., and Hamm, H E. (1993). NMR Structure of a Receptor-Bound 
G Protein Peptide. Nature 363, 276-280.
Erspamer, V. (1966). Occurrence of indolealkylamines in nature, p. 132-181. In V.
Erspamer (ed.), 5-Hydroxytryptamine and Related Indolealkylamines,. Handbook 
o f Experimental Pharmacology: 19.
Fargin, A., Raymond, J.R., Lohse, M.J., Kobilka, B.K., Caron, M.G., and Lefkowitz, R.J. 
(1988). The Genomic Clone G-21 Which Resembles a Beta-Adrenergic Receptor 
Sequence Encodes the 5-HTl A Receptor. Nature 335, 358-360.
Farrens, D. L., Altenbach, C., Yang, K., Hubbell, W.L., and Khorana, G. (1996). 
Requirement of Rigid-Body Motion of Transmembrane Helices for Light 
Activation of Rhodopsin. Science 274, 768-770.
Fletcher, A., Bill, D. J., Bill, S. J., Cliffe, I. A., Dover, G. M., Forster, E. A., Haskins, J. 
T., Jones, D., Mansell, H. L. & Reilly, Y. (1993). WAY100135: a novel, selective 
antagonist at presynaptic and postsynaptic 5-HTl A receptors. Eur J  Pharmacol 
237,283-291.
Gaddum, J. H. & Picarelli, Z. P. (1997), Two kinds of tryptamine receptor. 1957. B rJ  
Pharmacol 120, 134-139; discussion 132-133.
Glennon, R. A., Teitler, M., and Sanders-Bush, E. (1992). Hallucinogens and 
Serotonergic Mechanisms. NIDA Res. Monographs 119, 131-135.
Hayataka, K., O'Connor, M.-F., Kinzler, N., Weber, J.T., and Parker, K.K. (1998). A
Bioactive Peptide from the Transmembrane 5/Intracellular Loop 3 Region of the 
Human 5HTla Receptor. Biochem. Cell Biol 76, 657-660.
Hoyer D, C. D., Fozard JR, Hartig PR, Martin GR, Mylecharane EJ, Saxena PR,
Humphrey PP. (1994). International Union of Pharmacology classification of 
receptors for 5-hydroxytryptamine. Pharmacology Rev 46, 157-203.
78
Klein, D. (1991). Panic Disorder and Agoraphobia: Hypothesis Hothouse. Journal o f 
Clinical Psychiatry 57, 21-27.
Kobilka, B. K., Frielle, T., Collins, S., Yang-Feng, T., Kobilka, T.S., Francke, U., 
Lefkowitz, R.J., and Caron, M.G. (1987). An Intronless Gene Encoding a 
Potential Member of the Family of Receptors Coupled to Guanine Nucleotide 
Regulatory Proteins. Nature 329, 75-79.
Lembo, P. M., Ghahremani, M. H., Morris, S. J. & Albert, P. R. (1997). A conserved
threonine residue in the second intracellular loop of the 5-hydroxytryptamine 1A 
receptor directs signaling specificity. Mol Pharmacol 52, 164-171.
Maguire, M. E., Van Arsdale, P. M. & Gilman, A. G. (1976). An agonist-specific effect 
of guanine nucleotides on binding to the beta adrenergic receptor. Mol Pharmacol 
12, 335-339.
Marchese, A., George, S.R., Kolakowski, L.F., Lynch, K.R., and O'Dowd, B.F. (1999). 
Novel GPCRs and Their Endogenous Ligands: Expanding the Boundaries of 
Physiology and Pharmacology. Trends Pharm. Sci 20, 370-375.
Marglin, A. & Merrifield, R. B. (1970). Chemical synthesis of peptides and proteins. 
Annu Rev Biochem 39, 841-866.
Maricq, A. V., Peterson, A. S., Brake, A. J., Myers, R. M. & Julius, D. (1991). Primary 
structure and functional expression of the 5HT3 receptor, a serotonin-gated ion 
channel. Science 254, 432-437.
Marinissen, M. J. & Gutkind, J. S. (2001). G-protein-coupled receptors and signaling 
networks: emerging paradigms. Trends Pharmacol Sci 22, 368-376.
Martin, N. P., Leavitt, L.M., Sommers, C.M., and Dumont, M E. (1999). Assembly of G 
Protein-Coupled Receptors from Fragments: Identification of Functional 
Receptors with Discontinuities in Each of the Loops Connecting Transmembrane 
Segments. Biochem 38, 682-695.
Merkouris, M., Dragatsis, I., Megaritis, G., Konidakis, G., Zioudrou, C., Milligan, G. & 
Georgoussi, Z. (1996). Identification of the critical domains of the delta-opioid 
receptor involved in G protein coupling using site-specific synthetic peptides. Mol 
Pharmacol 50, 985-993.
Mulheron, J. G., Casanas, S.J., Arthur, J.M., Gamovskaya, M.N., Gettys, T.W., and 
Raymond, J R. (1994). Human 5-HTl A Receptor Expressed in Insect Cells 
Activates Endogenous Go-Like G Proteins. J. Biol. Chem 269, 12954-12962.
79
Nebigil, C. G., Gamovskaya, M. N., Casanas, S. J., Mulheron, J. G., Parker, E. M., 
Gettys, T. W. & Raymond, J. R. (1995). Agonist-induced desensitization and 
phosphorylation of human 5-HTl A receptor expressed in Sf9 insect cells. 
Biochemistry 11954-11962.
Onrust, R., Herzmark, P., Chi, P., Garcia, P. D., Lichtarge, O., Kingsley, C. & Bourne, H. 
R. (1997). Receptor and betagamma binding sites in the alpha subunit of the 
retinal G protein transducin. Science 275, 381-384.
Ortiz, T. C., Devereaux, M.C., and Parker, K.K. (1999). Coupling and G Protein
Activating Characteristics of a Human 5HTla Receptor i2 Loop Peptide. Soc for  
Neurosci Abstracts 25, 1466.
Ortiz, T. C., Devereaux, M.C., and Parker, K.K. (2000). Structural Variants of a Human 
5-HTl a Receptor Intracellular Loop 3 Peptide. Pharmacology 60, 195-202.
Palczewski, K., Kumasaka, T., Hori, T., Behnke, C. A., Motoshima, H., Fox, B. A., Le 
Trong, L, Teller, D. C., Okada, T., Stenkamp, R. E., Yamamoto, M. & Miyano,
M. (2000). Crystal structure of rhodopsin: A G protein-coupled receptor. Science 
289, 739-745.
Palm D, M. G., Malek D. (1995). Mapping G protein coupling domains by site-specific 
peptides. Meth Neurosci 25, 302-321.
Peroutka & S.J. (1995). 5-HT receptors: past, present and future. Trends Neurosci. 18, 
68-69.
Peroutka, S. J., Lebovitz, R. M. & Snyder, S. H. (1979). Serotonin receptor binding sites 
affected differentially by guanine nucleotides. Mol Pharmacol 16, 700-708.
Pierce, P. A., and Peroutka, S.J. (1989). Hallucinogenic Drug Interactions with
Neurotransmitter Receptor Binding Sites in Human Cortex. Psychopharmacology 
97.
Rapport MM, A. A. G., and Irvine H. Page. (1948). Serum vasoconstrictor (serotonin) IV. 
Isolation and characterization,. J. Biol. Chem 176, 1243-1251.
Raymond, J. R., Mukhin, Y.V., Gettys, T.W., and Gamovskaya, M.N. (1999). The
Recombinant 5-HTl a Receptor: G Protein Coupling and Signalling Pathways. 
Brit. J. Pharmacol. 127, 1751-1764.
Raymond, J. R., Olsen, C. L. & Gettys, T. W. (1993). Cell-specific physical and
functional coupling of human 5-HTl A receptors to inhibitory G protein alpha- 
subunits and lack of coupling to Gs alpha. Biochemistry 32, 11064-11073.
80
Sanders, K. M. (1998). G protein-coupled receptors in gastrointestinal physiology. IV. 
Neural regulation of gastrointestinal smooth muscle. Am J  Physiol 275, Gl-7.
Savarese, T. M. & Fraser, C. M. (1992). In vitro mutagenesis and the search for structure- 
function relationships among G protein-coupled receptors. Biochem J  283, 1-19.
Sheikh SP, Z. T., Lichtarge O, Sakmar TP, Bourne HR. (1996). Rhodopsin activation 
blocked by metal-ion-binding sites linking transmembrane helices C and F.
Nature 383, 347-350.
Shih JC, C. K., Gallaher TK. (1995). Molecular biology of serotonin receptors: A basis
for understanding and addressing brain function.Psychopharmacology. The fourth 
generation of progress. New York. 407-414.
Shulgin, A. T. (1969). Psychotomimetic Agents Related to the Catecholamines. J. 
Psychedelic Drugs 2, 14-19.
Soskin, R. A. (1975). Dipropyltryptamine in Psychotherapy, vol. 15. Grune and Stratton, 
New York.
Strader, C. D., Fong, T. M., Tota, M. R., Underwood, D. & Dixon, R. A. (1994).
Structure and function of G protein-coupled receptors. Annu Rev Biochem 63, 
101-132.
Taylor, J. M. & Neubig, R. R. (1994). Peptides as probes for G protein signal 
transduction. Cell Signal 6, 841-849.
Thompson, J. B., Wade, S.M., Harrison, J.K., Salafranca, M.N., and Neubig, R.R. (1998). 
Cotransfection of Second and Third Intracellular Loop Fragments Inhibit 
Angiotensin AT la Receptor Activation of Phospholipase C in HEK-293 Cells. J. 
Pharm. Exp Therap. 285 285, 216-222.
Unger, V. M., Hargrave, P.A., Baldwin, J.M., and Schertier, G.F.X. (1997).
Arrangements of Rhodopsin Transmembrane Alpha-Helices. Nature 389, 202- 
206.
van Zwieten, P. A., Blauw, G. J. & van Brummelen, P. (1990). Pathophysiological and 
pharmacotherapeutic aspects of serotonin and serotonergic drugs. Clin Physiol 
Biochem 8 SuppI 3, 1-18.
Varrault, A., Nguyen, D.L., McClue, S., Harris, B., Jouin, P., and Bockaert, J. (1994). 5- 
Hydroxytryptamine 1A Receptor Synthetic Peptides. J. Biol. Chem 24.
Weber, J. T., O'Connor, M.-F., Hayataka, K., Colson, N., Medora, R., Russo, E.B., and 
Parker, K.K. (1997). Activity of Parthenolide at 5HT2a Receptors. J. Nat. Prods 
60, 651-663.
81
Wieland, T., and Jacobs, K.H. (1994). Measurement of Receptor-Stimulated Guanosine 
S'-O-(gamma-thiophosphate) Binding by G Protein. Meth.Enzymol 217, 3-27.
Wishart, G., Bremner, D.H., and Sturrock, K.R. (1999). Molecular Modelling of the 5- 
Hydroxytryptamine Receptors. Receptors and Channels 6, 317-335.
Zifa, E. & Pillion, G. (1992). 5-Hydroxytryptamine receptors. Pharmacol Rev 44,401- 
458.
82
